Drug Profile
CD5 2
Alternative Names: CD5-2Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Mirrx Therapeutics; The Centenary Institute
- Developer Mirrx Therapeutics
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Gene expression inhibitors; MicroRNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for preclinical development in Solid-tumours in Denmark (IV, Injection)
- 11 Sep 2020 Preclinical development is ongoing for Solid tumours in Denmark (Mirrx Therapeutics pipeline, September 2020)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Solid-tumours in Denmark (IV, Injection)